Loading
Adenosquamous carcinoma of the cervix is an uncommon cervical cancer containing both gland-forming and squamous cancer cells. Like cervical adenocarcinoma it is caught less well by smear screening and does somewhat worse than squamous cancer stage for stage, but it is treated the same way, with surgery when early and chemoradiation when advanced.
The WHO classification of female genital tumours lists adenosquamous carcinoma among the HPV-associated cervical carcinomas, defined by both malignant glandular and squamous components. Cytology screening often fails to prevent adenocarcinoma; in a case-control study of 12,418 women with cervical cancer in England and Wales, being up to date with screening halved the odds of adenocarcinoma (odds ratio 0.46) and reduced advanced-stage adenocarcinoma more, and the paper treats adenosquamous carcinoma with adenocarcinoma (International Journal of Cancer 2016). In 148 patients with stage I to IVA adenocarcinoma or adenosquamous carcinoma treated with definitive radiotherapy, five-year relapse-free survival was 68 percent for non-bulky IB/IIA, 38 percent bulky IB/IIA, 49 percent IIB, 30 percent III and 0 percent IVA, inferior to squamous cell carcinoma, with distant failure common (Int J Radiat Oncol Biol Phys 2011).
How it differs from its parent: the parent page covers cervical cancer overall, three quarters squamous; adenosquamous carcinoma shares adenocarcinoma's screening blind spot and its worse radiotherapy outcomes, and its glandular component may raise the risk of ovarian and distant spread.
How common: no separate share in the sources read.
Treatment: as cervical cancer by stage on the parent and its early and recurrent pages: radical hysterectomy for early disease, cisplatin-based chemoradiation with brachytherapy for locally advanced disease, and platinum with pembrolizumab or bevacizumab for recurrent or metastatic disease; no histology-specific trial exists.
A minority of cervical cancers grouped with adenocarcinoma in most series; in England and Wales adenocarcinoma has become more common as squamous carcinoma declined under screening (International Journal of Cancer 2016). No separate share is in the sources read.
Most high-grade ovarian cancers begin at the tip of the fallopian tube; endometrial cancer lines the uterus, cervical cancer starts at the transformation zone; each drains to a different node group.
Same organ: Small cell neuroendocrine carcinoma of the cervix, Bartholin gland carcinoma, Vulvar melanoma, Vaginal melanoma, High-grade serous ovarian cancer, Low-grade serous ovarian cancer, Clear cell ovarian cancer, Mucinous ovarian cancer, Adult granulosa cell tumour of the ovary, Ovarian cancer, Endometrial cancer, Cervical cancer, Vulvar cancer, Gestational trophoblastic neoplasia, Uterine sarcoma, Vaginal cancer, POLE-ultramutated endometrial cancer, Mismatch-repair-deficient endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Advanced or recurrent endometrial cancer, Uterine carcinosarcoma, Early cervical cancer and fertility-sparing surgery, Locally advanced cervical cancer, Recurrent or metastatic cervical cancer, Platinum-sensitive ovarian cancer, Platinum-resistant ovarian cancer, HPV-associated vulvar squamous cell carcinoma, HPV-independent vulvar squamous cell carcinoma (p53-mutant), Vaginal squamous cell carcinoma (HPV-associated), Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Placental-site trophoblastic tumour and epithelioid trophoblastic tumour
Treated as cervical cancer by stage: radical hysterectomy when early, cisplatin chemoradiation with brachytherapy when locally advanced, platinum with pembrolizumab or bevacizumab when recurrent.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Adenosquamous carcinoma of the cervix" OR ABSTRACT:"Adenosquamous carcinoma of the cervix" OR TITLE:"Adenosquamous carcinoma" OR ABSTRACT:"Adenosquamous carcinoma" OR TITLE:"Adenosquamous cervical cancer" OR ABSTRACT:"Adenosquamous cervical cancer" OR TITLE:"Mixed adenocarcinoma and squamous cell carcinoma of the cervix" OR ABSTRACT:"Mixed adenocarcinoma and squamous cell carcinoma of the cervix") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Adenosquamous carcinoma of the cervix, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
Sudden severe abdominal pain, a hard or very tender abdomen, or abdominal pain with vomiting and fever. Boxed warning for gastrointestinal perforation on bevacizumab.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).
The shared side effects of drugs that block blood vessel growth (bevacizumab, ramucirumab and VEGFR kinase inhibitors): high blood pressure, protein leaking into the urine, nosebleeds and more serious bleeding, slow wound healing, and rarely holes in the bowel.
See all on the product pages:BevacizumabCisplatinPembrolizumab·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Adenosquamous carcinoma of the cervix, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.